Ieq Capital LLC Purchases New Shares in Exelixis, Inc. (NASDAQ:EXEL)

Ieq Capital LLC acquired a new position in Exelixis, Inc. (NASDAQ:EXEL) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 194,181 shares of the biotechnology company’s stock, valued at approximately $6,466,000. Ieq Capital LLC owned approximately 0.07% of Exelixis as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in EXEL. Blue Trust Inc. lifted its holdings in shares of Exelixis by 54.2% in the 3rd quarter. Blue Trust Inc. now owns 6,094 shares of the biotechnology company’s stock valued at $158,000 after acquiring an additional 2,141 shares during the last quarter. Raymond James & Associates raised its position in Exelixis by 118.2% during the third quarter. Raymond James & Associates now owns 239,661 shares of the biotechnology company’s stock valued at $6,219,000 after purchasing an additional 129,805 shares during the period. Signaturefd LLC lifted its stake in shares of Exelixis by 12.2% in the 3rd quarter. Signaturefd LLC now owns 6,138 shares of the biotechnology company’s stock valued at $159,000 after purchasing an additional 666 shares during the last quarter. Lecap Asset Management Ltd. purchased a new position in shares of Exelixis in the 3rd quarter worth approximately $326,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its position in shares of Exelixis by 18.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,317 shares of the biotechnology company’s stock valued at $268,000 after purchasing an additional 1,620 shares during the last quarter. 85.27% of the stock is currently owned by institutional investors.

Insider Activity

In related news, EVP Jeffrey Hessekiel sold 60,000 shares of the company’s stock in a transaction on Friday, November 29th. The stock was sold at an average price of $36.67, for a total transaction of $2,200,200.00. Following the completion of the sale, the executive vice president now directly owns 486,059 shares in the company, valued at $17,823,783.53. This represents a 10.99 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, Director Mary C. Beckerle sold 12,210 shares of Exelixis stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $34.88, for a total value of $425,884.80. Following the completion of the transaction, the director now owns 30,406 shares in the company, valued at $1,060,561.28. This trade represents a 28.65 % decrease in their position. The disclosure for this sale can be found here. Insiders own 2.85% of the company’s stock.

Exelixis Trading Up 0.1 %

EXEL opened at $35.09 on Friday. The company has a market capitalization of $9.82 billion, a price-to-earnings ratio of 19.82, a PEG ratio of 1.10 and a beta of 0.53. Exelixis, Inc. has a 12-month low of $20.14 and a 12-month high of $37.59. The business’s fifty day simple moving average is $34.16 and its 200-day simple moving average is $31.14.

Exelixis (NASDAQ:EXEL) last issued its earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%. On average, equities research analysts predict that Exelixis, Inc. will post 2.04 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. JMP Securities restated a “market outperform” rating and issued a $41.00 price target on shares of Exelixis in a research report on Thursday, January 23rd. Guggenheim restated a “buy” rating and issued a $42.00 target price on shares of Exelixis in a report on Wednesday, February 12th. Barclays upped their price target on shares of Exelixis from $25.00 to $29.00 and gave the company an “equal weight” rating in a report on Thursday, February 13th. Piper Sandler increased their price objective on shares of Exelixis from $37.00 to $38.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 12th. Finally, HC Wainwright restated a “buy” rating and set a $40.00 target price on shares of Exelixis in a research report on Thursday, February 13th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $37.24.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.